These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 34298787)

  • 21. Modulation of cellular radiation responses by histone deacetylase inhibitors.
    Karagiannis TC; El-Osta A
    Oncogene; 2006 Jun; 25(28):3885-93. PubMed ID: 16462761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy.
    Adeshakin AO; Adeshakin FO; Yan D; Wan X
    Front Immunol; 2022; 13():781660. PubMed ID: 35140716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
    Pojani E; Barlocco D
    Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic heterogeneity in cancer.
    Guo M; Peng Y; Gao A; Du C; Herman JG
    Biomark Res; 2019; 7():23. PubMed ID: 31695915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies.
    Burmeister A; Stephan A; Alves Avelar LA; Müller MR; Seiwert A; Höfmann S; Fischer F; Torres-Gomez H; Hoffmann MJ; Niegisch G; Bremmer F; Petzsch P; Köhrer K; Albers P; Kurz T; Skowron MA; Nettersheim D
    Mol Cancer Ther; 2022 Nov; 21(11):1674-1688. PubMed ID: 35999659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts.
    Schuetze KB; Stratton MS; Blakeslee WW; Wempe MF; Wagner FF; Holson EB; Kuo YM; Andrews AJ; Gilbert TM; Hooker JM; McKinsey TA
    J Pharmacol Exp Ther; 2017 Apr; 361(1):140-150. PubMed ID: 28174211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
    Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
    Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The epigenetic alteration and the effect of HDAC inhibitors in multiple myeloma].
    Terui Y
    Nihon Rinsho; 2015 Jan; 73(1):124-9. PubMed ID: 25626317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HDAC inhibitors in cancer care.
    Tofilon PJ; Camphausen K
    Oncology (Williston Park); 2010 Feb; 24(2):180-5. PubMed ID: 20361469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetics in non-small cell lung cancer: from basics to therapeutics.
    Ansari J; Shackelford RE; El-Osta H
    Transl Lung Cancer Res; 2016 Apr; 5(2):155-71. PubMed ID: 27186511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells.
    Sharda A; Rashid M; Shah SG; Sharma AK; Singh SR; Gera P; Chilkapati MK; Gupta S
    Clin Epigenetics; 2020 Jan; 12(1):4. PubMed ID: 31900196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy.
    Shen L; Pili R
    Oncoimmunology; 2012 Sep; 1(6):948-950. PubMed ID: 23162767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
    Cappellacci L; Perinelli DR; Maggi F; Grifantini M; Petrelli R
    Curr Med Chem; 2020; 27(15):2449-2493. PubMed ID: 30332940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
    Chang J; Varghese DS; Gillam MC; Peyton M; Modi B; Schiltz RL; Girard L; Martinez ED
    Br J Cancer; 2012 Jan; 106(1):116-25. PubMed ID: 22158273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics.
    Gupta R; Ambasta RK; Kumar P
    Life Sci; 2020 Sep; 256():117912. PubMed ID: 32504755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Epigenetic Perspective on Intra-Tumour Heterogeneity: Novel Insights and New Challenges from Multiple Fields.
    Beyes S; Bediaga NG; Zippo A
    Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of histone deacetylases and their inhibitors in cancer biology and treatment.
    Beumer JH; Tawbi H
    Curr Clin Pharmacol; 2010 Aug; 5(3):196-208. PubMed ID: 20406169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
    Schneider-Stock R; Ocker M
    IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
    Zain J; O'Connor OA
    Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S58-78. PubMed ID: 21132350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.